With the rapid advancement of diabetes technology, the number of patients with type 1 diabetes (T1D) using automated insulin delivery (AID) systems is increasing, making the presence of such patients in the perioperative period more common. This study presents two cases of T1D patients who underwent thyroidectomy while using AID, following a protocol designed in collaboration with the diabetology, anesthesiology, and surgical teams. Two female patients, aged 12 and 33 years, both using AID systems, were admitted for elective thyroidectomy. Glycemic metrics prior to surgery indicated good glycemic control, leading to the decision to continue AID during the procedures. The use of AID enabled safe surgical performance with satisfactory glycemic control. In one case, a continuous glucose monitoring (CGM) sensor disruption likely resulted from acetaminophen distribution and/or sensor's proximity to the surgical field. This report highlights the need for standardized guidelines regarding the use of AID in the perioperative period.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/jdi.14379 | DOI Listing |
Can J Diabetes
January 2025
Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address:
Aims: Attainment of the A1C target of ≤7.0% is consistently low among those living with type 1 diabetes (T1D). We evaluated endocrinologists' acceptability and implementation of A1C targets.
View Article and Find Full Text PDFActa Diabetol
January 2025
Department of Emergency, Tianjin Fifth Central Hospital (Peking University Binhai Hospital), Tianjin, 300450, China.
Aim: The outcomes of automated insulin delivery (AID) systems in pregnant women with type 1 diabetes (T1D) have not been systematically evaluated. This study aims to evaluate the efficacy and safety of AID in pregnancy.
Material And Methods: Literature searches were conducted until July 5, 2024, on Embase, PubMed, Cochrane Library, and ClinicalTrials.
J Clin Endocrinol Metab
January 2025
Children's Hospital of Philadelphia, Philadelphia, PA, 19104.
Objective: Glycemic outcomes in youth with type 1 diabetes (T1D) in the United States using the two most common automated insulin delivery (AID) systems, Insulet Omnipod 5 (OP5) and Tandem Control IQ (CIQ), have not been compared. We performed the first head-to-head analysis of changes in glycemic metrics among youth initiating AID.
Methods: This single center, retrospective study included youth <21 years with T1D, who started OP5 or CIQ between 1/2020 and 12/2023, and had ≥70% CGM active time.
Nat Med
January 2025
Division of Endocrinology & Metabolism, McGill University Health Centre, Montréal, Quebec, Canada.
Acta Diabetol
January 2025
1st Paediatric Department, School of Medicine, Faculty of Health Sciences, Ippokratio General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Aims: To assess the efficacy and safety of automated insulin delivery (AID) systems compared to standard care in managing glycaemic control during pregnancy in women with Type 1 Diabetes Mellitus (T1DM).
Methods: We searched MEDLINE, Cochrane Library, registries and conference abstracts up to June 2024 for randomized controlled trials (RCTs) and observational studies comparing AID to standard care in pregnant women with T1DM. We conducted random effects meta-analyses for % of 24-h time in range of 63-140 mg/dL (TIR), time in hyperglycaemia (> 140 mg/dl and > 180 mg/dL), hypoglycaemia (< 63 mg/dl and < 54 mg/dL), total insulin dose (units/kg/day), glycemic variability (%), changes in HbA1c (%), maternal and fetal outcomes.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!